Recommendations for the treatment of schizophrenia with negative symptoms. Standards of pharmacotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 1.

Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 1.

Journal

Psychiatria polska
ISSN: 2391-5854
Titre abrégé: Psychiatr Pol
Pays: Poland
ID NLM: 0103314

Informations de publication

Date de publication:
30 Jun 2019
Historique:
entrez: 16 9 2019
pubmed: 16 9 2019
medline: 27 2 2020
Statut: ppublish

Résumé

Schizophrenia is a chronic illness that in the majority of cases begins either in adolescence or early adulthood. It is often perceived as a severe, incurable condition with generally poor prognosis, while patients suffering from it tend to be agitated, aggressive and unpredictable in their behaviors. Growing awareness, along with gradual changes in the approach to the need for multifaceted schizophrenia therapy, as well as considerable progress in pharmacotherapy in recent years have allowed for improving the prognosis for many patients. Because of polymorphic character of the condition, many schizophrenia sub-types are identified by means of classifications of mental disorders, adjusting the criteria and descriptions to most frequently observed clinical scenarios. Clinical descriptions of schizophrenia are based on various psychopathological models, which are often multidimensional and multifactorial. They virtually always take account of the following two dimensions: negative (deficit) and positive (creative) symptoms. Contemporary approach to schizophrenia treatment assumes multidirectional therapeutic intervention aimed at achieving full remission and the patient's return to full psychosocial functioning. Long-term studies indicate that the severity of negative symptoms is the prognostic indicator of the deterioration of social and professional functioning and reduced quality of life. The following paper presents the review of concepts and research devoted to negative symptoms in schizophrenia and their treatment; in the second part, international standards and recommendations of the Polish Psychiatric Association concerning the approach to effective management of negative symptoms in schizophrenia are discussed.

Identifiants

pubmed: 31522193
pii: 100698
doi: 10.12740/PP/OnlineFirst/100698
pii:
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article Practice Guideline Review

Langues

eng pol

Sous-ensembles de citation

IM

Pagination

497-524

Auteurs

Agata Szulc (A)

Warszawski Uniwersytet Medyczny, Wydział Nauki o Zdrowiu, Klinika Psychiatryczna.

Jerzy Samochowiec (J)

Pomorski Uniwersytet Medyczny w Szczecinie, Katedra i Klinika Psychiatrii.

Piotr Gałecki (P)

Uniwersytet Medyczny w Łodzi, Klinika Psychiatrii Dorosłych.

Marcin Wojnar (M)

Warszawski Uniwersytet Medyczny, Katedra i Klinika Psychiatryczna.

Janusz Heitzman (J)

Instytut Psychiatrii i Neurologii, Klinika Psychiatrii Sądowej.

Dominika Dudek (D)

Uniwersytet Jagielloński Collegium Medicum, Klinika Psychiatrii Dorosłych.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH